News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
To make sure it is safe and effective in patients, psilocybin therapy needs to be approved by medical regulators, not legislators.
The cost of developing psilocybin therapy, with clinical trials in multiple countries, is significant, and involves considerable risk and resource. We think it’s an investment worth making.
Psilocybin therapy is unusual because it’s an innovative protocol that combines a medicine with psychological support.
Here we explain our full commitment to Open Science, including publishing the results from all our trials and supporting the publication of all results from independent studies that use our psilocybin.
Our therapist training programme has been designed by experts from the fields of psychology, psychiatry and psychedelic therapy research.